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The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway
and has been implicated in the pathogenesis of a variety of cancers. An important V600E mutation has been
identified and can cause constitutive B-Raf activation. Recent studies have evaluated a variety of small molecule
inhibitors targeting B-Raf, including PLX4032/vemurafenib, dabrafenib, LGX818, GDC0879, XL281, ARQ736, PLX3603
(RO5212054), and RAF265. Therapeutic resistance has been identified and various mechanisms described. This
review also discussed the current understanding of B-Raf signaling mechanism, methods of mutation detection,
treatment strategies as well as potential methods of overcoming therapeutic resistance.Discovery of Raf
The first Raf gene (v-Raf ), characterized from murine
sarcoma virus 3611 in 1983 by Mark and Rapp, was
named after the discovery of its role in fibrosarcoma in
newborn MSF/N mice [1]. Two years after its discovery,
the first functional human homolog of the v-Raf gene,
specifically C-Raf-1, was cloned from human cells. The
C-Raf-1 gene, also known as Raf-1, is composed of
80,626 base pairs of DNA with 17 exons on chromo-
some 3p25, which encodes a 3,291 nucleotide mRNA
and 648 amino-acid peptide molecule (http://www.
genecards.org). Subsequent to the discovery of C-Raf-1,
the A-Raf and B-Raf isoforms were characterized [2,3].
The A-Raf gene (ARAF1), also termed PKS or PKS2, is
located on X chromosome p11.4-11.2 and encodes a
1821 nucleotide mRNA and 606 amino-acid peptide
molecule (http://www.genecards.org). Human B-Raf,
located on chromosome 7q34, is composed of 18 exons
and encodes a 2,949 bp length mRNA and 766 amino-acid
residue peptide. Classically known as a serine/threonine
protein kinase, B-Raf has also been classified as proto-
oncogene B-Raf for murine sarcoma viral (v-Raf) oncogene
homolog B1, and B-Raf proto-oncogene serine/threonine-
protein kinase (p94). An inactive pseudogene (B-RAFP1,
3,356 bp, Gene ID: 286494) is located on chromosome
Xq13 [4]. A-Raf, B-Raf and C-Raf belong to a protein-
serine/threonine kinase family that along with their down-
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pathway [5]. Each Raf isoform shares three conserved
domains (Figure 1), including the N-terminus domain CR1,
containing Ras-binding and cystine-rich domains; CR2,
which is serine/threonine rich and contains a 14-3-3 bind-
ing site; and CR3, which is a conserved C-terminus domain
that acts as a protein kinase and has a stimulatory 14-3-3
binding site [2]. There is 76% homology between the amino
acid sequences of B-Raf and C-Raf, and 74% similarity
between B-Raf and A-Raf [6].
Wild-type Raf functions by forming a homodimer or
heterodimer with A-, B- and C-Raf isoforms (for more
detail, refer to [2]). These dimers can up-regulate MEK1
or MEK2 which further act on ERK1 or ERK2, respect-
ively. The diverse dimer patterns and their downstream
diverse molecules make the Raf signal pathway very
sophisticated. The Raf/MEK/ERK kinase signal pathway
is highly involved in cell proliferation, differentiation and
tumorigenesis [2]. Raf, including B-Raf, can regulate
multiple downstream molecules and is also regulated by
a variety of signaling molecules. Multiple transcription/
signaling molecules such as p53, AP-1, NF-KappaB,
C/EBPalpha, STAT3, c-Jun, have specific binding sites in
the B-Raf promoter and may regulate B-Raf expression
[7-9]. The B-Raf related PI3K/AKT/mTOR and Ras/Raf/
MAPK signaling pathways and potential targets for
treatment, as well as the structural domains of the B-Raf
isoform are summarized in the Figure 1.
Raf mutations in tumors
While mutations of A-Raf and C-Raf are generally rare
in neoplasia, mutations of B-Raf have been detected in aLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited.
Figure 1 B-Raf protein and signaling pathways. The B-Raf
protein and its related signaling pathway are shown along with
potential targets for treatment. A) The PI3K/AKT/mTOR and Ras/Raf/
MAPK signaling pathways are shown along with potential targets.
B) The structural domains of the B-Raf isoforms are shown. The
position of the V600E mutation is indicated (arrow).
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detected in approximately 45% of papillary thyroid
carcinoma (PTC) [10], 50-80% of melanoma [11], ~100%
of hairy cell leukemia, 11% of colorectal cancer and 41%
of hepatocellular carcinoma [12-15]. Solid tumor masses
can contain heterogeneous concentrations of stromal
/non-neoplastic cells in comparison to leukemia, and
may dilute the percentage of cells with mutant B-Raf
[10]. It is important to note that a single Raf mutation
without Ras activation provides an ideal candidate for
targeted therapy since mutant Raf signals as a monomer
[16]. However, if one monomer of the homodimer/
heterodimer in a normal Raf protein is bound to the Raf
inhibitor, the other monomer in the dimer can still be
transactivated and continue to stimulate its downstream
signaling pathway. Thus a sole B-Raf inhibitor will not
work in this situation. For the B-Raf V600E mutation,
Raf inhibitor binds to the sole Raf monomer and blocks
its signal transduction.
Even though over 70 different B-Raf mutations have
been detected, the V600E (T1799A) mutation in exon 15
is predominant in a variety of tumors [17]. Due to three
extra nucleotides found in GC rich exon 1 of B-Raf
DNA, the original V599E was changed to the V600E
[17]. V600E mutation in the kinase domain results inconstitutive Ras-independent activation of B-Raf, thereby
facilitating signal transduction within the downstream
MAPK kinase pathway and promoting cancer develop-
ment [18,19]. B-Raf mutations involving V600E accounts
for 68% and 80% of the mutation events in metastatic
and primary melanoma, respectively [20].
Despite the importance of B-Raf in carcinogenesis, the
role of this protein as a driver mutation remains contro-
versial. A study conducted in 65 different melanotic
lesions at different stages including nevi, radial growth
phase (RGP), vertical growth phase (VGP) melanomas
and melanoma metastases, revealed that B-Raf mutation
was detected in only 10% of early stage or RGP mela-
noma. This suggests that B-Raf mutations correlated with
progression rather than initiation of human melanoma
[21]. Later, in a conditional B-Raf V600E mutation mouse
model, it was shown that the expression of mutated B-Raf
induced the formation of benign melanocytic hyperplasia
[22]. However, these hyperplasia did not evolve into
melanoma over 15-20 months. In the same study,
concomitant PTEN silencing along with B-Raf mutation
caused rapid melanoma development and metastasis.
These findings suggest that B-Raf mutations could occur
early in the progression of melanoma yet it is unclear
exactly what effect these mutations have on this disease.
B-Raf gene mutations are also commonly detected in
thyroid carcinoma. The first study of B-Raf V600E in
papillary thyroid carcinoma (PTC) detected such mutation
in 24/35 (69%) of cancers [23]. Additionally, there is sub-
stantial evidence showing V600E mutation in classic PTC,
but not with follicular thyroid carcinoma and medullary
thyroid carcinoma [24-26]. Later studies showed that the
mutation rate was about 45%. Further studies showed that
this mutation had a strong relationship with poor progno-
sis including recurrence, nodal or distant metastasis and
upgraded staging as well as shortened long term survival
in PTC [26,27]. Similar to melanoma, the role of V600E as
an early driver mutation or later event in PTC remains
controversial [28]. In one study, B-Raf mutation was
detected in lymph nodes with metastatic PTC while the
primary PTC was negative for the mutation, which
suggested the mutation is a late event [29]. On the
contrary, in animal models of PTC, the expression of
mutant B-Raf V600E alone could initiate the development
of PTC [30,31]. A very recent study found that this B-Raf
mutation prevalence was 56.9% in 72 PTC cases, and
more importantly, the B-Raf V600E allele was detected in
5.1% to 44.7% of samples, suggesting again that B-Raf
mutation was a late event [32]. In the same study, it was
shown that N-, or K-Ras mutation could co-exist with B-
Raf V600E mutation in very small percentage of cases.
The authors did not exclude the possibility that Ras or Raf
mutation came from different cells. This observation
might also explain why resistance to B-Raf inhibitors
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ant to B-Raf inhibitors. Further study by the same group
showed that the higher the percentage of mutant B-Raf
allele in the tumor, the worse the long-term survival of the
patient with this mutation [33].
B-Raf mutation was recently reported in hairy cell
leukemia. Tiacci et al. detected B-Raf V600E mutation
in all hairy cell leukemia samples studied (n = 47) with
whole-exome sequencing of CD19 positive leukemic
cells [34]. None of 195 patients with other peripheral B
cell lymphoma carried the same mutation. Further study
with leukemic cells from 5 patients showed that Raf
inhibitor RLX4720 significantly lowered levels of phos-
phorylated MEK and ERK, indicating that in hairy cell
leukemia, mutated B-Raf was most likely the trigger for
constitutive MEK and ERK activation. Similar findings
from another study by a pyrosequencing assay showed
that B-Raf V600E mutation in classic hairy cell leukemia
was seen in 79% of samples [35]. The investigators
excluded the cases which had hairy cell leukemia in <10%
of total peripheral blood cells, therefore the sensitivity
could not explain the difference of these two studies.
Detection methods of B-Raf mutations
Various methods have been investigated for the detec-
tion of B-Raf mutations, with more recent techniques
showing greater sensitivity and throughput [10]. Sanger
sequencing is traditionally a reliable method and con-
sidered the “gold standard” technique for mutation
detection [36]. This technique has low throughout and
requires several distinct steps, namely PCR amplification
with dideoxynucleotide end termination, amplicon
purification, and sequence reading. Each of these steps
exposes samples to risk of contamination, and has low
analytical sensitivity of 10-20% [36,37]. A newer tech-
nique including pyrosequencing, the technique used for
the next generation of sequencing, was found to be
superior to direct sequencing in detecting B-Raf muta-
tions when a low abundance of mutant templates were
present [38]. However, pyrosequencing requires expen-
sive equipment thereby making it impractical for most
laboratories. Nonetheless, the advantage of sequencing is
that other variants beyond V600E can also be detected
in a single run.
Two other traditional methods for B-Raf mutation
detection include the PCR-restriction fragment length
polymorphism (PCR-RFLP) and PCR single-strand con-
formation polymorphism (PCR-SSCP) assays. PCR-RFLP
utilizes sequence amplification and enzymatic digestion
followed by comparison to known DNA sequence
samples. PCR-SSCP involves sequence amplification and
sample electrophoresis in order to exploit base pair
differences resulting in secondary cDNA structure alter-
ations. These two are labor-intensive and requireconsiderable personnel experience to employ. PCR-RFLP
has a detection sensitivity of 1-3% for detecting
mutations of B-Raf V600E [39,40], while the PCR-SSCP,
by incorporating with Sanger sequencing, has a sensiti-
vity of 5% [15].
Newer methods are emerging in the detection of gene
mutations in clinical samples. Shifted termination assay
(STA) was developed by the TrimGen Corporation
involving rapid analysis of a 96-well microplate using a
fluororimetric detection [41]. The three mutations in the
BRAF gene V600E, A, or G can be accurately detected
by both fluorescent color and fragment size. The sensi-
tivity is 1–5%.
Allele-specific PCR is another category of mutation
detection methods with the advantage of mutant enrich-
ment and high sensitivity. The goals of these methods
are to increase sensitivity, specificity and to accurately
quantify mutations of B-Raf V600E. One type of allele-
specific PCR is the amplification refractory mutation
system (ARMS)-PCR, a highly sensitive, specific and
low-cost method for detecting B-Raf mutations. Using
this technique, our laboratory recently developed an
ARMS-PCR test for V600E with a sensitivity of 0.5%
[10]. In a single tube, four primers are added to generate
three products with one serving as control and favoring
mutant product forming by adjusting more mutant
specific primer. With the advance of real-time technique,
Lang et al., developed an ARMS real-time PCR method
with a sensitivity of ~1% [42]. Morandi et al. developed an
allele-specific locked nucleic acid (LNA) quantitative PCR
assay using LNA-modified allele specific primers and
LNA-modified beacon probes [36]. Furthermore, the
detection sensitivity was 0.1% and the entire procedure
can be completed in 3 hours. This method was success-
fully used for monitoring circulating B-Raf mutation in
melanoma patients after biochemotherapy [43].
A few commercial kits are available to detect B-Raf
mutations. Dual-priming oligonucleotide (DPO)-based
multiplex PCR [37] is used in Seeplex B-Raf auto-
capillary electrophoresis detection system. The DPO
system has two separated primer segments with the 5′
segment being longer than the 3′ segment. The two
joined by a non-annealing poly(I) linker. The longer 5′
segment preferentially binds to the template DNA and
initiates stable annealing, whereas the shorter 3′
segment selectively binds to its target site and can speci-
fically target V600E mutations, thereby avoiding non-
specific annealing. The declared sensitivity is 2% [44].
Furthermore, Qiagen distributed an assay for B-Raf
V600E, Ecomplex, D, K or R mutation using a Rotor-Gene
Q (RGQ)-PCR kit with real-time PCR on the RGQ instru-
ment (Qiagen BRAF RGQ PCR Handbook). Using ARMS
and scorpions technologies, this method has a sensitivity
of 1.27%. The CobasW 4800 BRAF V600 mutation test
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with real-time PCR.
B-Raf inhibitors in early phase development
Recent developments in targeting B-Raf are changing
the treatment of various oncological diseases. A first
generation multi-target kinase inhibitor, sorafenib
(Nexavar, or BAY 43-9006), was initially developed as a
Raf inhibitor and tested for melanoma [45,46]. However,
this agent failed to yield a significant improvement in
survival as a single drug. Further investigation revealed
that sorafenib also targeted VEGFR, PDGFR, Flt-3, c-kit
and FGFR-1 [47]. Recently, sorafenib was approved for
the treatment of renal cell carcinoma and hepatocellular
carcinoma mainly because of anti-angiogenesis effects
rather than Raf inhibition [5,48,49].
The second generation of Raf inhibitors has improved
selectivity and efficacy (Figure 2). PLX4032’s activity
against B-Raf V600E mutation yielded intense excite-
ment for melanoma therapy. PLX4032 binds the ATP-
binding domain of mutant B-Raf monomer and, under
the condition that Ras is not constitutively activated, can
block MEK and ERK signaling [50,51]. Potent anti-
cancer effects are balanced against side-effects including
skin rash, and the development of squamous cell carci-
noma in about 30% of patients [5].
Several novel small molecules targeting mutant B-Raf
are being actively evaluated in preclinical models and
early clinical trials (Table 1; clinicaltrials.gov). GDC0879
was tested in 130 tumor cell lines and tumor bearingFigure 2 B-raf inhibitors in clinical development.mice [52]. The results revealed that the inhibitory
function was associated strictly with the B-Raf V600E
status of the cells. The treatment improved the survival
rate of mice harboring the B-Raf mutant tumor
MEXF989 compared to the mutant K-Ras–expressing
tumor MEXF535.
LGX818 is a potent and selective RAF kinase inhibitor
with little activity against wild-type BRAF. In vitro
studies showed no significant activity against a panel of
100 kinases (IC50 > 900 nM). LGX818 did not suppress
the growth of > 400 cell lines expressing wild-type BRAF.
LGX818 treatment at oral doses as low as 6 mg/kg in
human melanoma xenograft models (BRAFV600E) resul-
ted in strong and sustained (>24 hours) decrease in
pMEK [53]. A Phase I clinical trial in patients with
BRAF mutant tumors is ongoing (NCT01436656).
XL281 is a selective inhibitor of RAF kinase with anti-
tumor activity in xenograft models. A phase I clinical
study of XL281 orally once daily on a 28-day cycle in
patients with colorectal (CRC), melanoma, papillary
thyroid (PTC) and NSCLC [54]. The dose escalation phase
enrolled 30 pts. DLTs included fatigue, nausea, vomiting,
and diarrhea at the dose 225 mg. The MTD was 150 mg.
The most common treatment-related AEs included Grade
1/2, fatigue (48%), diarrhea (35%), nausea (35%), vomiting
(35%) and anorexia (30%). Severe AEs included hypoka-
lemia, nausea, and vomiting. Biomarker studies from
paired biopsies from 4 pts (3 melanoma, 1 NSCLC)
showed decreases in pMEK, pERK, and Ki67. MTD of
XL281 was established at 150 mg.
Table 1 B-Raf inhibitors in phase I/II clinical trials
Drugs Disease Clinical trial ID*
LGX818 Advanced melanoma NCT01436656
Dabrafenib (GSK2118436) Solid tumors NCT00880321
XL281 Solid tumors NCT00451880
ARQ-736 Advanced solid tumors NCT01225536
RO5212054 (PLX3603) Advanced solid tumors NCT01143753
RAF265 Advanced melanoma NCT00304525
*details available at www.clinicaltrials.gov.
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inhibitor. This small molecule is a potent inhibitor of
mutant BRAF (V600E), wild-type BRAF and c-RAF, in
colon, melanoma and thyroid cancer cell lines as well as
in xenograft mouse models [55,56]. A phase I clinical
study has been initiated.
PLX3603 (RO5212054) is also being tested in a phase I
clinical trial in patients with advanced solid tumors
(NCT01143753) [57].
RAF265 represents a novel oral small molecule dual
inhibitor of mutant BRAFV600E (EC50 = 0.14 μM) and
VEGFR2 (EC50 = 0.19 μM). RAF265 was demonstrated
in B-CPAP thyroid cancer cells to abrogate downstream
ERK signaling [58]. Furthermore, this study showed that
RAF265 also inhibited RET activity. When combined
with phosphoinositol-3-kinase (PI3K)/ mammalian target
of Rapamycin (mTOR) inhibitor BEZ235, a synergistic
effect leading to decreased cell proliferation was observed.
A first-in-human dose escalation study was done in 76
patients to identify MTD, PK, PD and anti-tumor activity
of RAF265 [59]. Different schedules were tested: daily
(QD), weekly and intermittent. 8 dose levels were admi-
nistered. Six of the 71 evaluable pts reported DLTs within
1st cycle (28 days): pulmonary embolism (2), visual distur-
bances (2), hyperlipasemia (1), diarrhea (1) and ataxia (1).
Grade III and IV thrombocytopenia was found to be also
dose limiting. In conclusion, the MTD of oral RAF265
was determined to be 48 mg daily. An intermittent sche-
dule at 67 mg higher dose is being explored.
B-Raf inhibitors in phase III studies
In 2011, the competitive small molecule serine/threo-
nine kinase inhibitor, vemurafenib (Zelboraf, PLX4032),
was approved by FDA for the treatment of patients with
unresectable or metastatic melanoma harboring the B-
Raf V600E mutation [60]. Vemurafenib was tested in a
phase III clinical trial in 132 metastatic melanoma
patients (Table 2). Among them, 122 patients were
harboring B-Raf V600E and 10 harboring V600K muta-
tion. The dose was 960 mg orally twice daily until the
development of unacceptable toxic effects or disease
progression. The overall response rate was 53% in a
12.9-month follow-up period (range 0.6 to 20.1). Themedian duration of response was 6.7 months, and median
progression-free survival was 6.8 months. Importantly,
only 14% of patients had disease progression. The
common side effects of vemurafenib included grade 1 or 2
arthralgia, rash, photosensitivity, fatigue and alopecia.
Unfortunately, 26% of patients developed cutaneous
squamous-cell carcinoma in the trial.
The reversible B-Raf inhibitor, dabrafenib (GSK2118436),
which selectively inhibits B-Raf V600E mutant, was recently
investigated in clinical trials [61-63]. Dabrafenib was given
at 150 mg twice daily in the phase II part of a phase I/II
study [64]. Cutaneous squamous carcinoma was observed
in 11% of the patients in the study. The authors concluded
that dabrafenib was safe in patients with solid tumors, and
was an active inhibitor of V600-mutant BRAF with
responses noted in patients with melanoma, brain metasta-
ses, and other solid tumors.
The phase III study of dabrafenib was a randomized
controlled trial among 250 patients with metastatic
melanoma harboring B-Raf V600E [61]. In the study,
187 patients received dabrafenib and 63 (37 male and 26
female) patients received dacarbazine for comparison.
The dose was oral dabrafenib 150 mg twice-daily or
intravenous dacarbazine 1000 mg/m2 every 3 weeks.
Dabrafenib -treated group reached 5.1 month of median
progression-free survival versus 2.7 months with dacar-
bazine. Dabrafenib achieved a 50% response rate while
the dacarbazine control group only achieved 6%.
Treatment-related side effect occurred in 53% and 44%
of patients in dabrafenib and dacarbazine groups, res-
pectively. This study also found 12 patients (6%) devel-
oped keratoacanthoma /squamous-cell carcinoma of the
skin in the dabrafenib group.
Recent studies have evaluated tumor samples after
treatment with these novel B-Raf inhibitors. A study of
21 tumor samples, 11 of them treated with vemurafenib,
found that keratoacanthoma or cutaneous squamous-cell
carcinoma developed as early as 3 weeks after vemura-
fenib treatment, with a mean incubation time of 10 weeks
[65]. The Ras mutation was detected in 13 samples with
12 containing H-Ras mutation. Further biochemical ana-
lysis showed that tumor specimen had higher ERK phos-
phorylation than surrounding normal skin. Vemurafenib
was also used to treat murine cell line B9 harboring H-Ras
mutation and found to paradoxically increase MAPK
signaling and cell proliferation. The effect of B-Raf
inhibitor on carcinoma formation was further confirmed
by the spontaneous tumor formation in animal treated by
DMBA-TPA, a known H-Ras mutation inducer with or
without PLX4720, a B-Raf inhibitor [65]. DMBA-TPA and
PLX4720 combination reduced the latency of the squa-
mous cell carcinoma formation and PLX4720 paradoxi-
cally increased MAPK signal in the cell lines harboring
mutated H-Ras [65].
Table 2 B-Raf inhibitors in phase III clinical trials
Drugs/regimen Diseases Dosage Clinical trial ID*
Dabrafenib Advanced melanoma Dabrafenib NCT01682083
(GSK2118436) 150 mg BID NCT01584648
+Trametinib (GSK1120212) ±Trametinib 2 mg OD for 12 months NCT01597908
Vemurafenib (PLX4032) Advanced melanoma Vemurafenib 960 mg BID NCT01597908
+ Dacarbazine ±Dacarbazine 1000 mg/m2 IV Q3weeks for 12 months NCT01667419 NCT01689519
+ GDC-0973 ± GDC-0973 60 mg QD for 21 of 28 days NCT01006980
Sorafenib Renal cell carcinoma Sorafenib 400 mg BID NCT00478114
+multiple combinations Hepatocellular carcinoma +multiple combinations NCT01135056
Acute myeloid leukemia NCT01371981
Stage III/IV melanoma NCT00111007
Non-small cell lung cancer NCT00449033
Pancreatic cancer NCT00541021
*details available at www.clinicaltrials.gov.
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the clinical efficacy of B-Raf inhibitors. Activation of the
Ras/Raf/MAPK pathway plays an important role in
cancer development. Theoretically, interference of this
pathway might achieve an anti-tumor effect, which is at
least, partially true in cell culture, xenograft tumor
models, and clinical specimens [18,66]. Raf and MEK
inhibitors can decrease this signaling pathway, and
therefore lead to clinic effects [50,67,68]. In another
clinical study of 37 specimens from 15 patients, a raf
inhibitor significantly increased CD4 and CD8 lym-
phocyte infiltration in the tumor. The increase of CD8
lymphocytes was correlated with reduction of tumor
volume and increase of necrosis [69].
Mechanisms of resistance to B-Raf inhibitors
Raf inhibitors have shown clinical efficacy in B-Raf V600E
containing melanoma. Resistance to Raf inhibitors has
been a widely explored topic. Multiple mechanisms of
resistance are being uncovered [18,70].
Interestingly, Raf inhibitors suppress the ERK signaling
in mutant B-Raf cells but enhance ERK signaling in
wild-type B-Raf cells. B-Raf inhibitors bind to one
member of the C-Raf/B-Raf heterodimer or C-Raf/C-Raf
homodimer. While inhibiting one protomer (partner),
this allows transactivation of the other drug-free proto-
mer [50]. It is generally accepted that the Ras and B-Raf
mutation is mutually exclusive. Therefore in B-Raf
mutated tumors, Ras is not activated. Thus, transactiva-
tion of wild-type Raf with Ras is minimal. It is hypothe-
sized that Ras activity levels in B-Raf V600E tumors may
not be high enough to support the transactivation of
ERK signal [50]. In one study, Raf inhibitors did not
inhibit ERK signaling in cells co-expressing B-Raf V600E
and mutant Ras [50]. These results suggest that an
increase in Ras activation or Raf dimerization may besufficient to cause drug resistance. Because of
heterogenicity of tumors, detection of cells with mutant
B-Raf does not exclude the possibility that the other
tumor cells could harbor wild-type B-Raf or mutant Ras.
The coexistance of different clones can lead to resistance
to B-Raf inhibitors. This has been confirmed by a recent
study which showed that B-Raf V600E allele only
accounted for 5.1-44.7% of B-Raf alleles in the papillary
thyroid carcinoma cells [32].
Altered parallel signaling has also been shown to
mediate resistance to B-Raf inhibitors. In one study,
chronic treatment with B-Raf inhibitor of the cell lines
induced resistance as the tumor cells with B-Raf muta-
tion can rewire their signaling properties by using any of
the three active Raf isoforms, i.e. A-Raf, B-Raf and C-Raf,
to trigger ERK activation [71]. In this study, inhibition of
one or two isoforms did not terminate ERK activity. The
resistant lines, however, showed enhanced IGF-IR/PI3K
signaling. Another report showed that in cells resistant to
vemurafenib, the levels of Ras-GTP, EKR and C-Raf as
well as phosphorylated AKT increased [18]. Interestingly,
this study demonstrated that a combination of vemura-
fenib with a MEK inhibitor showed a synergistic inhibitory
effect on the growth of both cells and tumor xenograft.
These constitute proof-of-principle that IGF-1R/PI3K/
AKT mediated signaling is associated with B-Raf inhibitor
resistance.
In addition, distinct mechanisms of MAPK activation
have been seen during B-Raf inhibitor treatment. Mutually
exclusive PDGFR beta receptor tyrosine kinase (RTK)-
mediated activation and Ras-mediated reactivation of the
MAPK pathway were also found to account for resistance
to B-Raf inhibitors [72]. This study utilized PLX4032-
resistant melanoma cell lines and further validated
findings in clinical tumors and tumor matched cultures.
Moreover, by expressing 597 sequence-validated kinase
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harboring B-Raf mutation, treatment with the MAPK
agonist PLX4723 activated ERK primarily through a MEK-
dependent mechanism without Raf signaling, and there-
fore facilitated de novo Raf inhibitor resistance [73].
Another mechanism of resistance to vemurafenib relates
to V600E alternative splicing. In one study, splicing out
exon 4-8 but retaining RAS binding domain generated a
new p61B-Raf (V600E) isoform, which had enhanced
dimerization in cells with low levels of Ras activation as
compared to full-length of B-Raf (V600E) [74]. This study
also showed that endogenous expression or ectopic induc-
tion of p61B-Raf (V600E) induced ERK signaling resistant
to vemurafenib, where disruption of p61B-Raf (V600E)
dimerization by site-directed mutation restored its sensi-
tivity to vemurafenib. More importantly, these authors
identified B-Raf (V600E) splicing variants lacking the
Ras-binding domain in 6 out of 19 patients with acquired
resistance to vemurafenib. This study further confirmed in
clinical specimens that alternative splicing is one of the
mechanisms of tumor resistance.Possible strategies to conquer resistance
Several strategies are being employed to overcome the
resistance to B-Raf inhibitors. The combination of B-Raf
inhibitor with a MEK inhibitor was found to have a syn-
ergistic or additive effect in both cell lines and xenograft
models [18]. Inactivation of IGF-IR/PI3K pathway, by
simultaneous MEK and IGF-1R/PI3K inhibition, has also
been shown to induce cell death in B-Raf resistant cells
[71]. It has been generally accepted that B-Raf and Ras
mutations tend to be mutual exclusive. Simultaneous
mutations of Ras and B-Raf have been reported [33].
These dual mutations along with Ras mutant/B-Raf wild
type cells pose resistance to Raf inhibitor and necessitate
different treatment strategies. Inhibiting combinations of
B-Raf and other key signaling molecules such as Ras, or
AKT may provide another way to overcome therapeutic
resistance [67]. Combination with radiotherapy and
general chemotherapy are also possible solutions.Conclusion and future directions
Significant progress has been made in the development
of Raf inhibitors, detection of common mutations, and
understanding the role of this key signaling molecule in
carcinogenesis. Novel inhibitors of downstream mole-
cules are undergoing active clinical trials [75].
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